Barcode Nanotech is a leading expert in one of the most pressing needs of RNA/DNA therapeutics – precise and safe delivery to target organs and cells. The company develops targeted delivery vehicles for next generation therapeutics. Our proprietary Lipid Nanoparticles (LNPs) enable precise target-site therapeutic activity, while our unique molecular barcoding-platform allows rapid and enhanced delivery optimization. Barcode's delivery vehicles are developed for selective indications such as hard-to-treat-cancers, metabolic diseases, fibrosis and other unmet diseases. The company has signed collaborative agreements with major drug companies for the development of RNA therapeutics. Our Solution: Barcode Nanotech is generating proprietary lipid nanoparticles (LNPs) that are designed to selectively reach target cells and tissues, while protecting the RNA molecules from degradation. Our LNPs are comprised of proprietary ionized lipids and formulations. Our nanoparticles formulations are generated and tested using a unique platform, comprised of the following key elements: (i) An AI-based platform for designing proprietary lipid nanoparticles - for selective delivery of RNA/DNA-therapeutics to target organs and cells (*proprietary ionized lipids + proprietary formulations) (ii) A high-throughput in vivo screening platform that enables rapid simultaneous testing and accurate delivery measurement of tens of particles in a single mouse (iii) LNP optimization platform